Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: David S. who wrote (3308)	12/13/1997 11:25:00 AM
From: JOHN W.	Respond to of 6136

<40 ARVs and PIs and 12 immue boosters. - (cut & paste from a newsgroup)> Please list all the PIs under development. It is not 40 (nice little trick) David. Please list all the PIs and their expected approval date. Furthermore, please explain why these PIs are under development if PIs will be obsolete soon, according to you. Until, you do, note that your little tricks are becoming quite tiresome.

To: David S. who wrote (3308)	12/13/1997 11:42:00 AM
From: JOHN W.	Read Replies (2) \| Respond to of 6136

------------------------------------------------------------------------ Title: Two Revised Documents Address the Use of Antiretroviral Agents in Pediatric and Perinatal HIV Infection are Now Available Source: AIDS Treatment Information Service (ATIS) (12/10/97) Abstract: The "Revised Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection" and the "Revised Recommendations for Use of Antiretroviral Drugs During Pregnancy for Maternal Health and Reduction of Perinatal Transmission of HIV-1." are now available in PDF format on the ATIS Web site at hivatis.org or in print by calling 1-800-448-0440 (TTY: 1-800-243-7012). Major Descriptors: Antiviral drugs. Pediatric AIDS. Perinatal transmission. Guidelines. ------------------------------------------------------------------------